MedTrace Logo

HRS-7450 Injection Phase II Clinical Trial for Acute Ischemic Stroke.

NCT07233070 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 208

Last updated 2025-11-20

No results posted yet for this study

Summary

This study plans to enroll a total of 208 patients with Acute Ischemic Stroke (AIS) who present within 4.5 to 24 hours of symptom onset and meet the specified imaging criteria.

Conditions

  • Acute Ischemic Stroke

Interventions

DRUG

HRS-7450 Injection

HRS-7450 Injection; low dose

DRUG

HRS-7450 Injection

HRS-7450 Injection; Intermediate dose

DRUG

HRS-7450 Injection

HRS-7450 Injection; high dose

DRUG

HRS-7450 Injection Placebo

HRS-7450 Injection Placebo

Sponsors & Collaborators

  • Fujian Shengdi Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-31
Primary Completion
2026-10-31
Completion
2027-01-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07233070 on ClinicalTrials.gov